CTD Holdings, Inc. companies provide Trappsol® brand cyclodextrins and Aquaplex® brand cyclodextrin complexes to researchers, R&D labs and industrial users in the medical, pharmaceutical, food, and nutritional industries. The symbol CTDH and trades on the OTCQB.
OTCQB:CTDH CTD Holdings, Inc. owns and acquires companies that develop, market, (and/or sell) products containing cyclodextrins (CDs). Cyclodextrins are rings of glucose molecules that bring oil and water together for applications requiring oil and water to work together seamlessly. Cyclodextrins can make existing consumer products “new and improved” by greatly enhancing the bio availability of vitamins or minerals and other characteristics. There are a myriad of commercial applications for this supra-molecular phenomenon including areas of agriculture, analytical chemistry, biotechnology, cosmetics, diagnostics, electronics, foodstuffs, pharmaceuticals, and the remediation of toxic waste. Over the last 20 years, CTD has established itself as a leading player in the marketing and sale of cyclodextrin chemistries. In 2010, the Company purchased a new plant in which to house its high volume pulse dryer (PD) with which it can manufacture CD complexes in commercial quantities, solving a major industrial supply challenge and transforming the Company into a high value, high volume manufacturer. Overview Quick Facts & Key Ratios 12-Month Trading Price High $.20 12-Month Trading Price Low $.03 Closing Price 10-28-2011 $.13 Shares Outstanding 8-11-2011 35,515,295 Float 8-11-2011 14,415,396 Market Capitalizaon $4,616,989 Enterprise Value $5,430,468 Last Quarter Revenue $369,000 TTM Revenue $1,094,000 Current Assets (Most Recent 10Q or 10K) $452,205 Current Liabilies (Most Recent 10Q or 10K) $226,750 Current Rao (Most Recent 10Q or 10K) 1.99 x Total Assets (Most Recent 10Q or 10K) $2,385,382 Total Liabilies (Most Recent 10Q or 10K) $955,383 Shareholder Equity (Most Recent 10Q or 10K) $1,429,999 CTD Holdings Inc. (United States) NanoSonic, Products CTD, Inc. Sphingo Biotechnology, Inc. Ferrazo Environmental
Transcript
OTCQB:CTDH
CTD Holdings, Inc. owns and acquires companies that develop, market, (and/or sell) products containing cyclodextrins (CDs). Cyclodextrins are rings of glucose molecules that bring oil and water together for applications requiring oil and water to work together seamlessly. Cyclodextrins can make existing consumer products “new and improved” by greatly enhancing the bio availability of vitamins or minerals and other characteristics. There are a myriad of commercial applications for this supra-molecular phenomenon including areas of agriculture, analytical chemistry, biotechnology, cosmetics, diagnostics, electronics, foodstuffs, pharmaceuticals, and the remediation of toxic waste.
Over the last 20 years, CTD has established itself as a leading player in the marketing and sale of cyclodextrin chemistries. In 2010, the Company purchased a new plant in which to house its high volume pulse dryer (PD) with which it can manufacture CD complexes in commercial quantities, solving a major industrial supply challenge and transforming the Company into a high value, high volume manufacturer.
Overview
Quick Facts & Key Ratios12-Month Trading Price High $.20
12-Month Trading Price Low $.03
Closing Price 10-28-2011 $.13
Shares Outstanding 8-11-2011 35,515,295
Float 8-11-2011 14,415,396
Market Capitalization $4,616,989
Enterprise Value $5,430,468
Last Quarter Revenue $369,000
TTM Revenue $1,094,000
Current Assets (Most Recent 10Q or 10K) $452,205
Current Liabilities (Most Recent 10Q or 10K) $226,750
Current Ratio (Most Recent 10Q or 10K) 1.99 x
Total Assets (Most Recent 10Q or 10K) $2,385,382
Total Liabilities (Most Recent 10Q or 10K) $955,383
Shareholder Equity (Most Recent 10Q or 10K) $1,429,999
CTD Holdings Inc.(United States)
NanoSonic,Products
CTD, Inc.Sphingo
Biotechnology, Inc.Ferrazo
Environmental
At the end of 2008, one of CTD Holdings’ customers provided one of its products in an effort to treat a set of twins in the U.S. who were diagnosed with Niemann Pick C (“NPC”). NPC is also called Childhood Alzheimer’s. It is a fatal disease caused by a genetic defect that prevents proper handling of cholesterol in the body’s cells. Harmful amounts of cholesterol accumulate in the spleen, liver, lungs, bone marrow, and brain. This excess of cholesterol causes progressive neurological deterioration with symptoms including dementia, seizures, ataxia and cataplexy. The patient’s treatment with Hydroxy-propyl-beta-cylcodextrin (HPBCD) (now called Trappsol Cyclo™) proved to provide an ameliorative benefit.
On May 17, 2010, the FDA granted orphan drug status for Trappsol Cyclo™ for the treatment of Niemann Pick Type C (NPC) disease to this customer. Under the Orphan Drug Act, companies that develop a drug for a disorder affecting fewer than 200,000 people in the United States may seek designation as an orphan drug and, if such application is approved, they have the ability to sell it without competition for seven years, and may get clinical trial tax incentives.
Important Note: This profile may contain forward-looking statements, particularly as related to pro forma financial statements, earnings estimates and business expectations, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward looking statements.” Forward look-ing statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. These forward-looking statements are only made as of the date of their release and CTD Holdings, Inc. does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
• Management Team are experts in the cyclodextrin market.• Strong Capital structure, Small Float, Management has lots of skin in
the game.• CTD recently completed its new manufacturing plant, allowing it to
produce bulk (commercial) amounts of cyclodextrin compounds. • Closed on Credit Facility Package with SunState Federal Credit Union
in March 2011. It consists of a $325,000 term loan with a $100,000 revolving line of credit.
• Owns a 40 acre farm that is for sale. When sold it will pay off the loan with SunState Federal Credit Union Immediately.
• World’s only Cyclodextrin Active Pharmaceutical Ingredient (API) • Orphan Drug Designation, used under Investigational New Drug (IND)• On the EPA National Contingency Plan List- Approved Products • cGMP Manufacturing of Food & Pharmaceutical Grades
